



**Pharmacy Updates
January-February 2019**

CenCal Health has made several changes to our Formulary based on clinical review, provider interest, cost and utilization analysis. All of the changes represent development and growth of our current Formulary thus giving more choices to the prescribing physician. The changes are represented in summary on the chart below.

Drug	Class	Formulary Status	Restrictions / Limits	Implementation Date
Formulary Additions				
Retacrit	Hematological Disorders	Formulary		1/1/2019
Epinephrine Auto Injector	Miscellaneous Agents	Formulary	Epinephrine 0.3mg/0.3ml Auto Injector Coding by NDC 49502-0500-01 Epinephrine 0.15mg/0.3ml Auto Injector Coding by NDC 49502-0501-01	1/1/2019
Lumoxiti 1mg vial	Neoplastic Disease	Formulary		1/1/2019
Udenyca 6mg/0.6ml syringe	Hematological Disorders	Formulary		2/1/2019
Dutasteride 0.5mg capsule	Benign Prostatic Hypertrophy	Formulary		2/1/2019
Formulary Changes				
Alfuzosin ER 10mg	Benign Prostatic Hypertrophy	Formulary	Removed Step Therapy	2/1/2019